STAAR Surgical (STAA) shares dropped ~10% despite beating Q2 preliminary sales estimates of $90M. Analysts from Jefferies, Needham, and BTIG cited lack of H2 guidance, cautious outlook comments, and macroeconomic uncertainties as reasons for maintaining Hold or Neutral ratings, overshadowing the positive earnings beat.